Skip to Content

Sapropterin Pregnancy and Breastfeeding Warnings

Sapropterin is also known as: Kuvan

Sapropterin Pregnancy Warnings

This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus; caution is recommended. AU TGA pregnancy category: B1 US FDA pregnancy category: C Comments: This drug should be considered only if dietary restriction of phenylalanine (Phe) is ineffective in reducing blood Phe levels.

Animal studies have failed to reveal clear evidence of teratogenic activity; however, in a rabbit study, an increase (not statistically significant) in the incidence of holoprosencephaly occurred with high doses. There are no controlled data in human pregnancy. Uncontrolled Phe levels above 600 mcmol/L in pregnant women were associated with very high rates of neurological, cardiac, facial dysmorphism, and growth anomalies in their infants. Dietary control of Phe levels during pregnancy is essential to reduce the rate of Phe-induced teratogenic effects. US: To monitor the outcomes of pregnant women exposed to this drug, a patient registry has been established. For additional information: 1-866-906-6100 AU TGA pregnancy category B1: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have not shown evidence of an increased occurrence of fetal damage. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Sapropterin Breastfeeding Warnings

AU, UK: Use is not recommended. US: Caution is recommended. Excreted into human milk: Unknown Excreted into animal milk: -IV: Yes -Oral: No Comments: The following should be considered: -The developmental and health benefits of human milk feeding -The mother's clinical need for this drug -Potential side effects in the human milk fed child due to the drug or the mother's underlying condition

See references

References for pregnancy information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. "Product Information. Kuvan (sapropterin)." BioMarin Pharmaceutical Inc, Novato, CA.
  3. Cerner Multum, Inc. "Australian Product Information." O 0

References for breastfeeding information

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. "Product Information. Kuvan (sapropterin)." BioMarin Pharmaceutical Inc, Novato, CA.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.